https://qilindo.com/wp-content/uploads/2021/12/ATLASense-REV-explainer-video.mp4

ATLASense

Remote PolyMonitor™

Play Video
Play Video

Video

Presentation

One Pager

Favorites

Raising

$6,000,000

in exchange for

18%

Industry

Medical

Company Size

20+

Patent

Yes

Location

Israel

Languages

English, Hebrew

Website URL​

ATLASense presents the RAPHAEL platform, a game-changer for continuous remote health surveillance.

The end-to-end solution based on the PolyMonitor™, an all-in-one non-invasive continuous single chest-worn wireless multi-sensor, enables detecting the very first signals of a wide range of deterioration scenarios.

ATLASense is the only one that develops a comprehensive ICU-grade platform that has widespread applications in pre, intra, and post-hospital settings versatile enough for clinicians to remotely customize for each particular patient at 10% of the cost-of-use compared to any other system.

The Vision

To become the standard of care in the remote patient monitoring industry.

The Product

The RAPHAEL platform is a cloud-based clinical decision support system that provides physicians with an actionable Data as a Service.

Current developed services include:

The most comprehensive remote ICU-Grade health surveillance platform – replacing dozens of expensive monitoring modalities, multiple-clinical indications, and a reusable solution.

RII (Respiratory Insufficiency Index) – a new and unique market for predicting respiratory failure earlier than any other biomarker – enables intervention for the prevention of respiratory deterioration.

Early detection of Sepsis – based on already proven LAURA AI software and the minute-by-minute monitoring stream data, to gain at least 25% reduction in overall mortality and $2 million in hospital savings on an annual average.

 

Overview

ATLASense presents the RAPHAEL platform, a game-changer for continuous remote health surveillance.

The end-to-end solution based on the PolyMonitor™, an all-in-one non-invasive continuous single chest-worn wireless multi-sensor, enables detecting the very first signals of a wide range of deterioration scenarios.

ATLASense is the only one that develops a comprehensive ICU-grade platform that has widespread applications in pre, intra, and post-hospital settings versatile enough for clinicians to remotely customize for each particular patient at 10% of the cost-of-use compared to any other system.

The Vision

To become the standard of care in the remote patient monitoring industry.

The Product

The RAPHAEL platform is a cloud-based clinical decision support system that provides physicians with an actionable Data as a Service.

Current developed services include:

The most comprehensive remote ICU-Grade health surveillance platform – replacing dozens of expensive monitoring modalities, multiple-clinical indications, and a reusable solution.

RII (Respiratory Insufficiency Index) – a new and unique market for predicting respiratory failure earlier than any other biomarker – enables intervention for the prevention of respiratory deterioration.

Early detection of Sepsis – based on already proven LAURA AI software and the minute-by-minute monitoring stream data, to gain at least 25% reduction in overall mortality and $2 million in hospital savings on an annual average.

 

The Team

Please Sign In or Register to view this content.

The Market

Please Sign In or Register to view this content.

Problem & Solution

Patients die because signs of deterioration and life-threatening events are overlooked or missed.

Respiratory deterioration has 6 stages.
Currently, the standard-of-care detects only the last 3 failure stages: 

  1. Respiration-rate 
  2. Increased CO2 in the blood
  3. Decreased O2 saturation in the blood

To enable early intervention and preventive care, we have developed and integrated a special sensor into the PolyMonitor that provides unique data which is the basis of our unique new marker. This enables early detection and warning on the first 4 out of the 6 deterioration stages. 

The first stage which is the earliest (1-3 days before any other marker) is based on changes in the diaphragm muscles’ electrical activity.

ATLASense is the only solution that detects these changes.

Please Sign In or Register to view this content.

A D D M Y S T A R T U P

Get Full Access

We need to know you better

Before we approve and open the option to send messages to all the startups, we need to know you better. please fill out the form:

Want to See More?

Sign up as an investor or add your startup to gain full access.
It’s absolutely free!

Don't Miss An Opportunity

Sign up as a investor and gain full access. It’s absolutely free!

New Report

Close